Compare Regeneron Pharmaceuticals Inc (REGN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Repligen Corporation Common Stock — how do they compare? Regeneron Pharmaceuticals Inc trades at $783.75 (market cap $77.54B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7× Repligen Corporation Common Stock's market cap, and Regeneron Pharmaceuticals Inc pays a 0.5% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Repligen Corporation Common Stock for 0 Days on average.
| REGN | RGEN | |
|---|---|---|
Market Cap | $77.54B | $11.14B |
Volume | 629,519 | 1,259,263 |
Sector | Health | Health |
52-Week High | $852.03 | $194.57 |
52-Week Low | $569.17 | $102.87 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $72.25B | $11.02B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $778.36, up 2.04% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant expansion of its immunology alliance with Sanofi, valued up to $8 billion, which could drive future growth. Valuation ratios appear reasonable, with a P/E of 18.64 and robust profitability margins.
The outlook for REGN is positive, supported by strong earnings momentum, a lucrative partnership expansion, and a unanimous analyst buy consensus. Key risks include competitive pressures in the biopharma space and reliance on key drug performance. The stock presents a compelling opportunity for growth investors, with a consensus price target of $849.84 suggesting upside potential.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
